A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Forteo

A Pilot Methodology Study To Evaluate Changes In Bone Quality Parameters Following Therapy With Recombinant Human Parathyroid Hormone, PTH (Forteo)

This methodology trial will be conducted in patients with osteoporosis and will measure the changes in bone quality parameters, micro- and macroarchitecture, bone biomarkers and bone density following therapy with the approved drug, Forteo.

Inclusion Criteria:

• Postmenopausal women with osteoporosis

Exclusion Criteria:

• Any therapies or products affecting bone turnover within 12 months of Screening.
• Bisphosphonate treatment >1 month in total duration at any time in the past.
• In addition, patients must be bisphosphonate-treatment-free for at least 12 months prior to Screening.